Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation

NCT04217135 is registered in ClinicalTrials.gov with Kaohsiung Veterans General Hospital. as lead sponsor.

NCT NCT04217135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04217135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation
Lead sponsor
Kaohsiung Veterans General Hospital.
Phase
Phase 4
Overall status
Unknown status
Start date
January 1, 2017
Completion date
July 31, 2022
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mitral regurgitation, systolic heart failure stage d (disorder)